These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 23955638)
1. Multiple sclerosis: Prospects and promise. Hauser SL; Chan JR; Oksenberg JR Ann Neurol; 2013 Sep; 74(3):317-27. PubMed ID: 23955638 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic decision making in a new drug era in multiple sclerosis. Keegan BM Semin Neurol; 2013 Feb; 33(1):5-12. PubMed ID: 23709208 [TBL] [Abstract][Full Text] [Related]
4. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs. Hyland M; Rudick RA Curr Opin Neurol; 2011 Jun; 24(3):255-61. PubMed ID: 21455068 [TBL] [Abstract][Full Text] [Related]
5. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials. Sørensen PS Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048 [TBL] [Abstract][Full Text] [Related]
6. Non-specific immunosuppressants in the treatment of multiple sclerosis. Confavreux C; Vukusic S Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781 [TBL] [Abstract][Full Text] [Related]
7. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Neuhaus O; Archelos JJ; Hartung HP Trends Pharmacol Sci; 2003 Mar; 24(3):131-8. PubMed ID: 12628358 [TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis: a review of existing therapy and future prospects. Khan OA J Pak Med Assoc; 1996 Jan; 46(1):20-4. PubMed ID: 8830165 [TBL] [Abstract][Full Text] [Related]
9. Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis. Nathoo N; Yong VW; Dunn JF Mult Scler; 2014 Jan; 20(1):3-11. PubMed ID: 24263386 [TBL] [Abstract][Full Text] [Related]
10. Intravenous polyclonal human immunoglobulins in multiple sclerosis. Soelberg Sorensen P Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269 [TBL] [Abstract][Full Text] [Related]
12. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Hemmer B; Hartung HP Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020 [TBL] [Abstract][Full Text] [Related]
13. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617 [No Abstract] [Full Text] [Related]
15. [Recent advances in pathogenesis and therapy of multiple sclerosis]. Linker RA; Stadelmann C; Diem R; Bähr M; Brück W; Gold R Fortschr Neurol Psychiatr; 2005 Dec; 73(12):715-27. PubMed ID: 16355314 [TBL] [Abstract][Full Text] [Related]
16. [Multiple sclerosis]. Offenhäusser M; Martin R Med Monatsschr Pharm; 1997 Jun; 20(6):149-57. PubMed ID: 9289627 [No Abstract] [Full Text] [Related]
17. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Schmierer K; Parkes HG; So PW; An SF; Brandner S; Ordidge RJ; Yousry TA; Miller DH Brain; 2010 Mar; 133(Pt 3):858-67. PubMed ID: 20123726 [TBL] [Abstract][Full Text] [Related]
18. Management of multiple sclerosis: current trials and future options. Noseworthy JH Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064 [TBL] [Abstract][Full Text] [Related]
20. The role of MRS and fMRI in multiple sclerosis. Tartaglia MC; Arnold DL Adv Neurol; 2006; 98():185-202. PubMed ID: 16400835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]